Our findings showed that gilteritinib induced deep molecular responses and FLT3‐ITD clearance, as defined by a low FLT3‐ITD allele burden, in heavily pretreated patients with FLT3‐ITD+ R/R AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.